Abstract 4278
Background
Specific anatomical locations of melanoma mets (MM) influence OS in pts treated with anti-PD-1 based immunotherapy (IT), but little is known about anatomical distribution of mets within a patient (patterns of MM). We investigated the clinical factors and OS associated with the patterns of MM.
Methods
Demographics, disease characteristics and patient outcomes were examined from MM pts. Univariate and multivariable (MVA) logistic regression was used to identify factors associated with patterns of MM. Cox proportional hazards method for OS analysis.
Results
6031 MM pts were studied; median age of 61yo, 66% male, 32% elevated LDH, 74% stage IV M1c/d. 17% had systemic treatment; IT (61%), targeted therapy (32%) and chemotherapy (7%) 1st line. Median FU was 57.5 months (mos) and the median OS (mOS) was 9.4 mos (untreated: 7.5 mos; treated: 39.4 mos). In MVA performed on untreated pts, elevated LDH (HR 1.5) and presence of brain (HR 1.5), liver (HR 1.8) and bone (HR 1.5) mets were associated with shorter OS; while gastrointestinal (GI) mets (HR 0.8) were associated with longer OS. Similar results were found for treated pts; but male pts had shorter OS (HR 1.3) and GI mets did not affect OS. Within all pts, mOS for pts with vs without brain mets was 8 vs 10 mos (p < 0.01), respectively; and mOS for pts with vs without liver mets was 7 vs 11 mos (p < 0.01), respectively. In untreated pts, brain mets were associated with adrenal mets, but not liver, GI, bone or subcutaneous (subcut); while in treated pts brain mets were associated with adrenal and subcut mets. Liver mets occurred frequently with bone, adrenal and spleen mets, and less frequently with brain, GI and subcut mets in untreated pts; while they were associated with bone and spleen mets in treated pts. Untreated pts with brain, liver or bone mets had longer mOS in the presence of GI mets (7 vs 11; 6 vs 8; 7 vs 11mos, respectively), while GI mets did not affect OS in treated pts. Treated pts with liver mets have shorter OS (22 mos) if bone (18 mos), adrenal (14 mos) or spleen (18 mos) mets are present, but this was not seen in untreated pts.
Conclusions
Both treated and untreated pts have distinct patterns of MM and survival. These data may help defining prognosis and provides insight to further studies on the biology of mets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melanoma Institute Australia.
Funding
Has not received any funding.
Disclosure
M.S. Carlino: Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Mass-Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche; Advisory / Consultancy: Aduro. All other authors have declared no conflicts of interest.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract